Adverse events associated with immune checkpoint inhibitors: clinical manifestations and mechanisms

Corresponding author: QIAN Yun, qianyun1985@zju.edu.cn

DOI: 10.12201/bmr.202502.00010

•  

  Abstract: Immune checkpoint inhibitors have demonstrated significant efficacy in various malignant tumors by selectively activating the patients own T lymphocytes against cancer cells. However, this activation can also lead to uncontrolled attacks on normal tissues and organs, resulting in immune-related adverse events of varying severity. This article aims to investigate the clinical manifestations and underlying mechanisms of these immune-related adverse reactions.

  Key words: Immune-related adverse events; Immune checkpoint inhibitors; Tumors; Immunotherapy

  Submit time: 10 February 2025

  Copyright: The copyright holder for this preprint is the author/funder, who has granted biomedRxiv a license to display the preprint in perpetuity.
• html

• 图表

• Wang Huan, Ma Ying, Tian Jingnan, Lu Yi. Progress in the Diagnosis and Treatment of Immune Checkpoint Inhibitor-Associated Hypothyroidism from the Perspectives of Traditional Chinese and Western Medicine. 2025. doi: 10.12201/bmr.202505.00004

  Li Ying, Wang Xiaofei, Lu Shengwei, Dong Danni, Zhang Jingfeng, Zheng Jianjun. CT Findings and Clinical Features of checkpoint Inhibitor-related pneumonitis. 2024. doi: 10.12201/bmr.202407.00008

  Houyu, Liyong, Zhouweixing, Liyaozaho, Lili. Progress in the study of cryoablation-induced immune effects and combined immunotherapy. 2025. doi: 10.12201/bmr.202503.00061

  Yadian Lei, Haiyan Wang. The Impact of the Tumor Immune Microenvironment on T Cell Function: Focusing on the Limitations of ICB and Combined Treatment Strategies. 2024. doi: 10.12201/bmr.202412.00083

  JIA Bei, DAI Yuanyuan. Sintilimab-induced Diabetes Ketoacidosis with multiple organ immune related adverse reactions:A Clinical Case. 2024. doi: 10.12201/bmr.202411.00022

  Clinical research progress of PD-1/PD-L1 inhibitor induction therapy in unresectable stage III non-small-cell lung cancer. 2025. doi: 10.12201/bmr.202501.00025

  gaoweiwei, lijialin, liudaijian, wangyulin. Correlational Analysis of Immune-Inflammatory Markers with the Clinical Outcomes of Severe Pneumonia. 2024. doi: 10.12201/bmr.202409.00062

  zhao li, yan yu ru, hao yu pei, liu yong li. Analysis of 237 cases of thyroid related adverse reactions induced by lithium carbonate. 2025. doi: 10.12201/bmr.202503.00087

  YOU Qing-hai. Construction of a TFF3-Related Prognostic Model for Lung Adenocarcinoma Based on Lasso-Cox Regression and Its Predictive Value for Immunotherapy. 2025. doi: 10.12201/bmr.202509.00054

  Bao Kaiwen. Research progress on DNA damage and immune response in autoimmune diseases. 2024. doi: 10.12201/bmr.202410.00007

• ID	Submit time	Number	Download
  1	2025-01-09	10.12201/bmr.202502.00010V1	Download

• Public  Anonymous  To author only Submit Comments